Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities

Fig. 3

Western blotting to probe the molecular mechanisms of effects of YL529 in vitro. a p-VEGFR3 in HLECs was detected after YL529 treatment by western blotting analysis. b The overexpression of VEGF-D in VEGF-D-LL/2 cells was confirmed by western blotting analysis. The molecular weight of full-length VEGF-D was 21 KD. c VEGF-D-LL/2 cell were treated with YL529, p-JNK/JNK, Bax, Bcl-2 were analyzed by western blotting analysis

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us